Medicure Inc. filed a suit against Nexus Pharmaceuticals Inc. for allegedly infringing its patent for drug Aggrastat.
Aggrastat, or tirofiban hydrochloride, is used to reduce blood clots in patients with acute coronary syndrome.
Medicure said it filed the case after Nexus sought the U.S. Food and Drug Administration's approval to market a generic version of Medicure's medicine. The patent for Aggrastat has not yet expired.
Medicure, a Canada-based pharmaceutical company, filed the case in the U.S. District Court for the District of Northern District of Illinois through its Medicure International Inc. unit.
Previously, Medicure sued India's Gland Pharma Ltd. for infringing the patent for Aggrastat. The case was settled in August.